• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NPL, Imperial College London launch virtual lab

NPL, Imperial College London launch virtual lab

November 10, 2017
CenterWatch Staff

NPL, the UK's National Measurement Institute (NMI), and SynbiCITE at Imperial College London, have announced the establishment of a new £7 million virtual lab to underpin their joint Centre for Engineering Biology, Metrology and Standards to help the UK synthetic biology industry improve the manufacturing and adoption of new products - in partnership with LGC and NIBSC.

The virtual lab is a new collaboration between institutes undertaking world-leading research in biological measurements, which positions UK as a global leader in the industrialization of synthetic biology: NPL, LGC, the UK's National Measurement Laboratory for chemical and bio-measurement, NIBSC and Imperial College London's SynbiCITE, the UK's National Industrial Translation Centre dedicated to the commercialization of synthetic biology. This new lab will develop and provide relevant reference materials and methods in the form of a toolbox aiming to improve the reproducibility of research results that will help convert innovation in synthetic biology into valuable products and services.

The lab is part of £17 million of new government funding announced by The Chancellor of the Exchequer two weeks ago to help translate the UK's scientific expertise into real life treatments, and will focus on accelerating the application of synthetic biology in life sciences.

As a burgeoning sector, synthetic biology cuts across different concepts, capabilities and technologies which need validating before they are ready for commercialization. There are also many variables to factor in when looking to scale-up the production of a synthetic biology product. All of these need to be referenced to standards to provide certainty in the consistency of the product performance, and confidence in the ability to measure and evaluate key performance parameters. These are the main attributes in deciding which products are adopted, and ultimately commercialized, by industry. Establishing industry-led measurements and standards will safe-guard the quality and safety of products, and allow companies to maintain competitiveness and enhance innovation. This innovation hub will further engage with industry to help transform high-value manufacturing into high-value products that will deliver economic and societal benefits.

This timely and critical investment will support the development of exactly these capabilities. Industry confidence in the higher order biological reference materials that are developed will be ensured through their validation and certification by the UK's National Measurement System (through NPL, LGC and NIBSC). Applications that will benefit most include advanced therapies such as gene, cell and regenerative therapies, as well as the discovery and manufacture of new antibiotics.

Each collaborating institute will offer its individual expertise to assist the UK in becoming the world leader in the industrialization of engineering biology. As the UK's NMI, NPL provides the framework, facilities and expertise to enable measurements at the molecular, cellular and sub-cellular levels to be reproduced with confidence. LGC and NIBSC will provide specialist expertise in biological standardization, in the form of genomic and bioactivity measurements, respectively.

Dr Michael Adeogun, Head of Life Sciences and Health at NPL, said: "A key point in the government's Life Sciences Industrial Strategy, launched in August, is the need for the development and quick adoption of innovative drugs and therapies. Synthetic biology offers great opportunities here but requires underpinning measurement to ensure that new products are realized and can be commercialized more quickly. Much as good measurement is vital to ensuring fair exchange of physical goods, it is also integral to establishing the same trusted exchange of knowledge, and therefore is an important factor in accelerating access to new innovations. NPL is delighted to announce the first phase of establishing the UK Centre for Engineering Biology, Metrology and Standards, to achieve this."

Professor Paul Freemont and Professor Richard Kitney, Co-Directors of SynbiCITE at Imperial College, said: "The new center is part of a wider collaboration with the NPL, LGC and NIBSC in Engineering Biology, Metrology and Standards. Synthetic Biology/Engineering Biology has, since 2013, been recognized by the Government as a key area for economic growth - for example as an important driver of the bioeconomy. We view the development of new metrology and standards for the field as being essential for effective industrial translation - through accurate reproducibility, coupled to high levels of reliability. The partnership with NPL (including LGC and NIBSC) is seen as being an essential step in this process."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing